StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Mylan (MYL) PT Raised to $45 at BTIG Following Copaxone Generic Approval
October 4, 2017 7:27 AM
BTIG analyst Timothy Chiang raised his price target on Mylan (NASDAQ: MYL) to $45.00 (from $42.00) while maintaining a Buy ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Analyst PT Change
Next Articles
Teva Pharma (TEVA) PT Lowered to $15 at Morgan Stanley
October 5, 2017 8:58 AM
Teva Pharma (TEVA) PT Lowered to $21 at Barclays; Generic Copaxone 40mg Approval 'Will Offset Some Contracting Strategies... Hurt Sentiment'
October 4, 2017 12:17 PM
Mylan (MYL) PT Raised to $36 at Cowen; Reiterates Market Perform
October 4, 2017 10:44 AM
Mylan's (MYL) Surprise Copaxone Generic Approval 'Quite Negative' for Teva Pharma (TEVA) - Mizuho
October 4, 2017 7:02 AM
Mylan (MYL): A Big Win - BMO
October 4, 2017 6:55 AM
Mylan surges, Teva slumps after FDA approves Copaxone copy
October 4, 2017 6:48 AM
Momenta Phama (MNTA) on Watch After Mylan (MYL) Granted FDA Approval of First Generic for Copaxone
October 4, 2017 6:42 AM
Teva Pharma (TEVA) volatility flat into Mylan (MYL) granted FDA approval of Copaxone
October 4, 2017 6:20 AM
Mylan (MYL) volatility flat into announces FDA approval of ANDAs for Glatiramer Acetate Injection
October 4, 2017 6:16 AM
Teva (TEVA) Shares Pressured After Mylan (MYL) Granted FDA Approval of First Generic for Copaxone
October 4, 2017 6:14 AM
Mylan (MYL) Granted FDA Approval of First Generic for Copaxone
October 4, 2017 5:49 AM
Mylan Announces U.S. FDA Approval of First Generic for Copaxone® 40 mg/mL 3-Times-a-Week and May Be Eligible for 180-Day Exclusivity
October 3, 2017 9:58 PM
